<div id="readability-page-1"><p>In a report released today, Laura Chico from Wedbush maintained a Buy rating on BioCryst, with a price target of <span id="expert-recommendation-target">$21.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Chico is a 5-star analyst with an average return of <span>11.6%</span> and a 51.56% success rate. Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, BioCryst, and Denali Therapeutics.</p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioCryst with a $19.27 average price target.</p></div>

BCRX

<p>Wedbush analyst Laura Chico maintained a Buy rating on BioCryst (BCRX) with a price target of $21.00. Chico, a 5-star analyst with an 11.6% average return, focuses on the Healthcare sector. The general analyst consensus for BioCryst is a Strong Buy with a $19.27 average price target.</p>

BioCryst (BCRX) Gets a Buy from Wedbush